SSA
TGTX icon

Schonfeld Strategic Advisors’s TG Therapeutics TGTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Buy
+65,213
New +$2.67M 0.01% 778
2026
Q1 		– Sell
-21,390
Closed -$638K – 2663
2025
Q4 		$638K Buy
21,390
+3,986
+23% +$130K ﹤0.01% 1299
2025
Q3 		$629K Buy
+17,404
New +$573K ﹤0.01% 1584
2025
Q2 		– Sell
-27,735
Closed -$1.09M – 2538
2025
Q1 		$1.09M Buy
+27,735
New +$933K 0.01% 1247
2024
Q4 		– Sell
-198,613
Closed -$4.65M – 2380
2024
Q3 		$4.65M Sell
198,613
-71,671
-27% -$1.57M 0.03% 569
2024
Q2 		$4.81M Sell
270,284
-220,814
-45% -$3.52M 0.03% 564
2024
Q1 		$7.47M Buy
491,098
+153,949
+46% +$2.45M 0.05% 481
2023
Q4 		$5.76M Sell
337,149
-1,030,251
-75% -$12M 0.04% 490
2023
Q3 		$11.4M Buy
1,367,400
+850,507
+165% +$11.9M 0.09% 312
2023
Q2 		$12.8M Sell
516,893
-548,320
-51% -$14.2M 0.11% 287
2023
Q1 		$16M Buy
1,065,213
+1,002,213
+1,591% +$15.2M 0.15% 189
2022
Q4 		$745K Buy
63,000
+23,652
+60% +$172K 0.01% 1314
2022
Q3 		$233K Sell
39,348
-396,983
-91% -$2.6M ﹤0.01% 2254
2022
Q2 		$1.85M Buy
+436,331
New +$2.72M 0.02% 769
2021
Q1 		– Sell
-23,537
Closed -$1.22M – 2122
2020
Q4 		$1.22M Buy
+23,537
New +$795K 0.02% 744
2020
Q3 		– Sell
-44,479
Closed -$867K – 1650
2020
Q2 		$867K Buy
44,479
+23,261
+110% +$375K 0.02% 643
2020
Q1 		$209K Buy
+21,218
New +$268K 0.01% 901
2018
Q2 		– Sell
-33,277
Closed -$472K – 965
2018
Q1 		$472K Buy
+33,277
New +$425K 0.04% 493

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Schonfeld Strategic Advisors's TGTX Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 65,213 shares worth $3.58M. The stake represents 0.01% of the portfolio and ranks #778 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in TGTX as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in TGTX in Q1 2018 and has held it in 18 quarters since. The position peaked at $16M in Q1 2023. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Schonfeld Strategic Advisors held 65,213 shares of TG Therapeutics worth $3.58M as of Q2 2026.
  • TG Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • TG Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #778 holding.
  • Schonfeld Strategic Advisors first reported a position in TG Therapeutics in Q1 2018 and has held it in 18 quarters since.
  • Schonfeld Strategic Advisors's TG Therapeutics position peaked at $16M in Q1 2023.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.